You are here
Samumed to Present Preclinical Data on SM07883, a Potential First-in-Class Alzheimer’s Disease Candidate, at the Alzheimer’s Association International Conference® (AAIC®) 2018
SAN DIEGO, July 17, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that it has been selected to present preclinical data on the company’s novel DYRK1a inhibitor, SM07883, a potential first-in-class drug for the treatment of Alzheimer’s disease. These data will be featured as an oral presentation at the Alzheimer’s Association International Conference® (AAIC®) 2018, to be held in Chicago from July 22-26, 2018.
“DYRK1a is an attractive drug target for the potential treatment of Alzheimer’s disease due to its Tau protein-modifying activity,” said Yusuf Yazici, M.D., Chief Medical Officer of Samumed. “We look forward to presenting our preclinical findings on SM07883, our DYRK1a inhibitor, with the research community attending AAIC. The data from treatment with SM07883 showed improvements in general health and performance of a complex motor coordination task in a mouse model of Alzheimer’s disease, compared with control animals.”
Oral presentation details:
|Abstract Title||Date/Time||Session Title|
|Tau Pathology Reduction with SM07883, a Novel, Potent, and Selective Oral DYRK1a Inhibitor - A Potential Therapeutic for Alzheimer’s Disease||Wednesday, July 25|
2:30 p.m. – 2:45 p.m. CDT
|Preclinical (nonhuman): |
Therapeutic Strategies for Frontotemporal Dementia
Further details can be found on the AAIC website at https://www.alz.org/aaic/. A copy of the presentation materials can be accessed by visiting the Publications section of the Samumed website following the conclusion of the conference.
About the Alzheimer’s Association International Conference (AAIC)
The Alzheimer’s Association International Conference® (AAIC®) is the largest and most influential international meeting dedicated to advancing dementia science. Each year, AAIC convenes the world’s leading basic science and clinical researchers, next generation investigators, clinicians and the care research community to share research discoveries that will lead to methods of prevention and treatment, and improvements in diagnosis for Alzheimer’s disease.
About Alzheimer’s Disease
Alzheimer’s disease (AD), the most common cause of dementia, is a chronic neurodegenerative disease affecting an estimated 5.5 million people in the US and over 46 million people worldwide. The disease is initially characterized by progressive memory loss and then slow progression to severe difficulty in accessing basic brain functions, prompting mental disorders. With the world’s aging population, AD is quickly becoming “The Disease of the Century,” a global epidemic and a socio-economic burden impacting families, social service, and healthcare delivery systems. Currently available therapies treat symptoms, not the disease itself, which is ultimately fatal.
SM07883 is an oral small molecule dual-specificity tyrosine phosphorylation-regulated kinase-1A (DYRK1a) inhibitor being developed for the treatment of Alzheimer’s disease. Preclinical data suggested that SM07883 reduced Tau phosphorylation, the effects of pathological Tau overexpression, and neuroinflammation. Additional information on Samumed’s SM07883 Alzheimer’s disease program can be found here: https://www.samumed.com/pipeline/detail.aspx?id=18
Samumed’s small-molecule drug platform is harnessing the innate restorative power of the Wnt pathway to reverse the course of severe and prevalent diseases. Learn more about Samumed’s potential regenerative drug candidates and broad clinical pipeline at https://www.samumed.com/pipeline/default.aspx
Matt Middleman, M.D.
LifeSci Public Relations